MedPath

Efficacy of 5% Trisodium Citrate and Low Dose Heparin as Catheter-Locking Solution for Central Venous Hemodialysis Catheters: A Randomized Controlled Study

Phase 4
Recruiting
Conditions
Central venous catheter dysfunction (CVC dysfunction) is failure to maintain the prescribed extracorporeal blood flow required for adequate hemodialysis without lengthening the prescribed HD treatment. A catheter locking anticoagulant (CLA) by trisodium citrate (TSC) or unfractionated heparin (UFH) is recommended in real practice to prevent this problem.
Central venous catheter dysfunction, CVC dysfunction, Catheter locking anticoagulant, CLA, Trisodium citrate, TSC, Unfractionated heparin, UFH
Registration Number
TCTR20231106002
Lead Sponsor
Thammasat University Research Fund
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
216
Inclusion Criteria

1. Hemodialysis patients, 2. Well-positioned of non-tunnel cuffed catheter (NTCC) or tunnel cuffed catheter (TCC) expected to be needed for more than 1 week without flow problems (a persistent inability to obtain blood flow rate [BFR] above 250 mL/minute)

Exclusion Criteria

1. Hemorrhagic diathesis conditions (liver failure, disseminated intravascular coagulopathy, leukemia, vitamin K deficiency, hemophilia, or thrombocytopenia), 2. Hypercoagulable states (deep vein thrombosis, pulmonary embolism, or antiphospholipid syndrome), 3. Hematologic diseases (paroxysmal nocturnal hemoglobinuria, myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis, or hemolytic anemia), 4. Metastatic cancer, 5. Currently using of oral contraceptive pills, 6. Currently using one of the following anticoagulants: warfarin, UFH, enoxaparin, rivaroxaban, apixaban, or dabigatran, 7. Proven or suspected heparin induced thrombocytopenia, 8. Allergic to UFH or TSC, 9. Pregnant, 10. Unable to obtain crucial data, 11. Refused to participate

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Rate of Catheter dysfunction (CD) At 3 months after end of the intervention Percentage
Secondary Outcome Measures
NameTimeMethod
Rates of catheter related blood stream infection(CRBSI) At 3 months after end of the intervention Percentage,Exit site infection (ESI) At 3 months after end of the intervention Percentage,Bleeding episodes At 3 months after end of the intervention Events
© Copyright 2025. All Rights Reserved by MedPath